Low levels of miR-5193 contribute to ESCC progression and poor outcomes and may serve as a biomarker reflecting tumor immune status and ICI-related outcomes.
Abstract
Esophageal Cancer: Molecular Biology/Pathology
Low levels of circulating tumor-suppressor microRNAs are associated with cancer progression and poor prognosis. However, their role in immune evasion and response to immune checkpoint inhibitors (ICIs) remains unclear.
We aimed to identify a PD-L1–targeting tumor-suppressor microRNA downregulated in esophageal squamous cell carcinoma (ESCC). Four tumor-suppressor microRNAs (miR-5193, miR-3117-3p, miR-802, and miR-651-3p) predicted to target programmed cell death ligand 1 (PD-L1) were selected.
Plasma levels of miR-5193 were significantly lower in ESCC patients than in healthy volunteers. In 122 consecutive ESCC patients, low plasma miR-5193 was associated with advanced tumor depth and pathological stage and was an independent prognostic factor. In ESCC cells, miR-5193 suppressed PD-L1 expression. In a co-culture model of tumor cells and T cells, miR-5193 overexpression enhanced T-cell antitumor activity by suppressing PD-L1. Among 56 ESCC patients treated with or without ICIs for recurrence, miR-5193 levels showed a trend toward an inverse association with PD-L1 tumor proportion score. In the low miR-5193 group, disease control rate was higher and ICI-treated patients showed a trend toward longer progression-free survival.
Low levels of miR-5193 contribute to ESCC progression and poor outcomes and may serve as a biomarker reflecting tumor immune status and ICI-related outcomes.
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality, largely due to late diagnosis, molecular diversity, and frequent development of treatment resistance. MicroRNAs (miRNAs) play critical roles in NSCLC initiation, progression, and treatment resistance. Previous studies have ide...
Maryam Abdipourbozorgbaghi, R. Radpour, S. Haefliger· Cancer Cell International· 0 citations
The miR-6838-5p/miR-195-5p combination represents a promising circulating miRNA signature for invasive ductal breast carcinoma and its consistent discriminatory performance in the discovery cohort and an independent serum cohort supports further evaluation in larger prospective studies.
Mustafa Barış Zeytunlu, Fazilet Esra Incedere Duzdag, Hüseyin Esin et al.· Molecular Biology Reports· 0 citations
BACKGROUND
c-MET overexpression is common in non-small cell lung cancer (NSCLC) and associated with poor prognosis, however, its role in immune evasion and immunotherapy resistance remains unclear.
METHODS
We analyzed c-MET expression in public "The Cancer Genome Atlas NSCLC" cohort (n = 1043) and an institutional co...
Li-Jin Chen, Xi-Hu Yao, Chun-Yan Su et al.· International Immunopharmaco...· 1 citation
The existing data about the involvement of three important miRNAs, miR-125b, miR-375 and miR-451 in breast cancer chemoresistance, based on the studies gathered from PubMed, Scopus and Web of Science up to December 2025 are summarized.
ABSTRACT Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis have transformed cancer therapy, but their efficacy remains limited in glioblastoma (GBM) and heterogeneous in colorectal cancer (CRC). MicroRNAs (miRNAs) regulate gene expression at the post-transcriptional level, including immune checkpoint mo...
Alja Zottel, M. Ždralević, Janja Rašović et al.· RNA Biology· 0 citations
Background Lymph node metastasis (LNM) is a critical factor contributing to poor prognosis in esophageal squamous cell carcinoma (ESCC) patients. Consequently, elucidating its molecular mechanisms and identifying effective therapeutic targets have become a paramount challenge in clinical practice. Methods Plasma sample...
Yao-Jie Wang, Yu-Ting Sun, Yu-Hui Fu et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.